CBD and BDNF Combination Shows Promise in Treating Alzheimer’s Disease
- The study from North Dakota State University found that early intervention with cannabidiol (CBD) and brain-derived neurotrophic factor (BDNF) delivered via targeted nanoparticles reduced key Alzheimer’s disease markers and improved cognitive function in an animal model.
- Researchers used a commonly studied Alzheimer’s disease animal model and emphasized early treatment, noting that biological changes begin 15-20 years before severe symptoms appear, making timing crucial for therapy effectiveness.
- The treatment involved four weekly doses of CBD and plasmid BDNF encapsulated in brain-targeting liposome nanoparticles, chosen for their anti-inflammatory, neuroprotective, and synaptic benefits.
- The combined treatment significantly reduced amyloid burden, inflammation, and microglial activation while increasing synaptic markers and hippocampal neurogenesis, resulting in improved cognitive performance; however, further research is needed before human application.
A study published today by the journal ACS Chemical Neuroscience by researchers from North Dakota State University found that an early intervention using cannabidiol (CBD) alongside brain-derived neurotrophic factor (BDNF) delivered through targeted nanoparticles reduced key markers tied to Alzheimer’s disease while also improving cognitive function.
The study focused on a commonly used animal model for Alzheimer’s disease, with researchers testing whether treatment earlier in the disease process could produce stronger results than therapies given after significant damage has already occurred. According to the researchers, many of the biological changes associated with Alzheimer’s begin 15 to 20 years before symptoms become severe, making early treatment a potentially important factor.
To test that approach, the team administered four weekly doses of a formulation containing CBD and plasmid BDNF encapsulated in liposome nanoparticles engineered for brain targeting. The researchers say CBD was chosen because of its anti-inflammatory and neuroprotective properties, while BDNF was included because reduced BDNF levels are associated with worsening pathology and cognitive decline in Alzheimer’s disease.
Compared to saline-treated mice, the treatment reduced amyloid burden by 3.04-fold. It also lowered levels of the pro-inflammatory cytokine TNF-α by 2.51-fold and IL-1β by 2.34-fold, while reducing microglial activation by 2.15-fold. In addition, the treatment increased synaptic marker levels and promoted adult hippocampal neurogenesis.
Researchers say these changes ultimately led to improved cognitive function in the mice, indicating that combining CBD with BDNF may represent a potential therapeutic strategy for Alzheimer’s disease when used early in the progression of the condition.
The findings add to a growing body of research examining whether cannabinoids and neuroprotective agents could play a role in slowing the biological processes linked to neurodegenerative disease, though further research would be needed before the approach could be considered for human use.